(Q80442187)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306836%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Can we reduce hypoglycaemia with insulin detemir? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306836%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

0 references

C Mathieu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306836%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306836%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

28 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306836%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

S35-40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306836%20AND%20SRC:MED&resulttype=core&format=json

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Adverse events and their association with treatment regimens in the diabetes control and complications trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Implementation of treatment protocols in the Diabetes Control and Complications Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Hypoglycemia is the limiting factor in the management of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

When oral agents fail: practical barriers to starting insulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Modeling phasic insulin release: immediate and time-dependent effects of glucose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Intellectual deficits associated with early onset of insulin-dependent diabetes mellitus in children.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802748

7 January 2021

Identifiers

DOI

10.1038/SJ.IJO.0802748

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15306836%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference